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Abstract Viroporins are a group of proteins that participate in
several viral functions, including the promotion of release of
viral particles from cells. These proteins also a¡ect cellular
functions, including the cell vesicle system, glycoprotein tra⁄ck-
ing and membrane permeability. Viroporins are not essential for
the replication of viruses, but their presence enhances virus
growth. Comprising some 60^120 amino acids, viroporins have
a hydrophobic transmembrane domain that interacts with and
expands the lipid bilayer. Some viroporins also contain other
motifs, such as basic amino acid residues or a domain rich in
aromatic amino acids that confers on the protein the ability to
interact with the interfacial lipid bilayer. Viroporin oligomeri-
zation gives rise to hydrophilic pores at the membranes of virus-
infected cells. As the list of known viroporins steadily grows,
recent research e¡orts focus on deciphering the actions of the
viroporins poliovirus 2B, alphavirus 6K, HIV-1 Vpu and in£u-
enza virus M2. All these proteins can enhance the passage of
ions and small molecules through membranes depending on their
concentration gradient. Future work will lengthen the list of
viroporins and will provide a deeper understanding of their
mechanisms of action.
/ 2003 Federation of European Biochemical Societies. Pub-
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1. Introduction
Viruses in£ict a number of injuries as they infect susceptible
cells. Some of these injuries a¡ect cell membranes, such that
the plasma membrane and intracellular vesicle system become
modi¢ed. A typical feature observed during the action of most
animal viruses is enhanced membrane permeability [1]. Several
viral gene products could be responsible for these changes,
including proteases [2,3], glycoproteins [4^7] and viroporins
[1].
2. De¢nitions and early work
Viroporins are small, highly hydrophobic, virus-encoded
proteins that interact with membranes modifying the cell’s
permeability to ions or other small molecules. The name vi-
roporin was ¢rst proposed when it was found that several
virus proteins shared common characteristics [8]. This concept
was later revised in depth [1].
That viroporins existed was predicted many years ago,
when enhanced membrane permeability was noted in several
virus^cell systems [9,10]. Two di¡erent modes of membrane
leakiness have been distinguished according to the time of
infection. Early membrane modi¢cation linked to virus entry
requires no gene expression since it is the virion’s components
that mediate these alterations [11,12]. As infection progresses,
several viral products can a¡ect cell membranes. Amongst
these products, viroporins are responsible, at least in part,
for membrane leakiness occurring late in infection.
3. General features of viroporin structure
Typically, viroporins are comprised of some 60^120 amino
acids (Table 1). They contain a highly hydrophobic domain
able to form an amphipathic K-helix. The insertion of these
proteins into membranes followed by their oligomerization
creates a typical hydrophilic pore with hydrophobic amino
acid residues facing the phospholipid bilayer and hydrophilic
residues forming part of the pore [13^16]. Apart from this
domain, there are several additional features of viroporin
structure that warrant mentioning. Hence, some viroporins
contain an additional hydrophobic region that interacts with
membranes. This may disturb the organization of the lipid
bilayer. The viroporin may also contain a stretch of basic
amino acids that acts like a detergent (Fig. 1). All these fea-
tures contribute to membrane destabilization.
Recently, another domain has been detected in some viro-
porins that has the capacity to interact with membranes. This
domain is rich in aromatic amino acids and is usually inserted
in the interfacial phase of the phospholipid bilayer [17]. This
type of interaction also leads to membrane destabilization,
thus enhancing membrane permeability.
4. Virus glycoproteins that modify membrane permeability
Several types of virus proteins are able to modify membrane
permeability. Sensu stricto, this property de¢nes the activity
of a viroporin. However, apart from small hydrophobic viral
proteins, there are other virus products that promote mem-
brane permeabilization. This is true of a number of virus
glycoproteins that are known to increase cell membrane per-
meability [4,6,7,18^22]. The architecture of some viral glyco-
proteins is such that, upon oligomerization, it may conform a
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physical pore. In principle, physical viral glycoprotein pores
could be formed by the fusion of peptides acting in conjunc-
tion with transmembrane domains. The fusion peptides would
create a pore in the cell membranes upon insertion, while the
transmembrane domain would form a pore in the virion mem-
brane. Moreover, domains adjacent to the transmembrane
region could have motifs designed to destabilize membrane
structure. Thus, in viruses that lack the typical viroporin, its
function could be replaced by these pore-forming glycopro-
teins, while for other viruses viroporin activity may be redun-
dant [23,24]. In the latter case, pore formation may be
achieved by both viral glycoproteins and viroporins. We
would like to propose the possibility that pore-forming glyco-
proteins play a key role mainly during virus entry and in some
cases also during virus budding, while viroporins come into
action when viruses need to exit the cell. In conclusion, some
viruses could have developed glycoprotein structures capable
of destabilizing membranes that totally or partially replace
viroporin function. Viroporin activity might be fully replaced
in viruses, such as HIV-2, that lack typical viroporins.
Besides these glycoproteins, there are currently about a doz-
en proteins that qualify as typical viroporins (Table 1). How-
ever, most work on the structure^function of viroporins has
concentrated on four of these proteins.
5. Picornavirus 2B
Picornavirus proteins arise from a large polyprotein precur-
sor that is cleaved by viral proteases [25]. The picornavirus 2B
gene codes for a protein of about 100 residues, depending on
the virus species considered (Table 1). The 2B product con-
tains two hydrophobic regions (Fig. 1). At least one of these
regions spans the membrane by means of an amphipathic
helix. Using the two-hybrid system, it was determined that
there are 2B homo-interactions [26,27]. The formation of 2B
homo-oligomers has been con¢rmed by an elegant approach
involving £uorescence resonance energy transfer microscopy
[28]. In fact, it seems that most of the 2B protein located at
membranes oligomerizes as dimers and tetramers [14]. It was
initially shown that both poliovirus 2B and 3A proteins had a
permeabilizing e¡ect on cells, though attention soon turned to
just the 2B protein [29,30]. Notably, the 2BC precursor is the
most permeabilizing viral protein, perhaps due to the confor-
mation adopted by 2B in this precursor, or to di¡erences in
the subcellular location of 2B and 2BC, or to an intrinsic, still
unveiled activity of 2BC [31,32]. Certainly 2C alone is devoid
of permeabilizing capacity in cells. All three proteins, 2B, 2BC
and 3A, interact with membranes and are found to mostly
localize at intracellular membranes [33^36]. The subcellular
location of each of these proteins when individually expressed
may be altered by co-expression of combinations of the three
[37].
Not only do 2B, 2BC and 3A enhance membrane perme-
abilization, but they are also able to promote intracellular
Table 1
List of several viroporins, indicating the number of amino acid residues and some references
Virus family Viroporin AA residues References
Picornaviridae Poliovirus 2B 97 [29,30,32,98]
Coxsackievirus 2B 99 [27,99,100]
Poliovirus 3A 87 [29,30]
Togaviridae SFV 6K 60 [45]
Sindbis virus 6K 55 [17]
Ross River virus 6K 62 [15]
Retroviridae HIV-1 Vpu 81 [60,62]
Paramyxoviridae HRSV SH 64 [84]
Orthomyxoviridae In£uenza A virus M2 97 [13,70,72,80]
Reoviridae ARV p10 98 [85]
Flaviviridae HCV p7 63 [86,87]
Phycodnaviridae PBCV-1 Kcv 94 [90,91]
Rhabdoviridae BEFV alpha 10p 88 [92]
SFV, Semliki forest virus; HIV-1, human immunode¢ciency virus type 1; HRSV, human respiratory syncytial virus; ARV, avian reovirus;
HCV, Hepatitis C virus; PBCV-1, Paramecium bursaria chlorella virus; BEFV, bovine ephemeral fever virus.
Fig. 1. Sequences of selected viroporins. Boxes indicate hydrophobic
regions. Basic amino acid residues are shown in bold and some aro-
matic residue clusters are underlined.
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membrane remodeling [33^35,38], leading to disruption of the
vesicle system and glycoprotein tra⁄cking, including the ex-
pression of receptors on the cell surface [30,39]. Unfortu-
nately, poliovirus lacking the 2B gene is not viable, since
intracellular membrane remodeling is a prerequisite for viral
genome replication [35]. Poliovirus and coxsackievirus 2B and
2BC variants have been analyzed in detail [32,36].
Using liposomes, it has been possible to estimate the size of
the pore formed by 2B at 6 AO in diameter [14]. This pore size
allows the di¡usion of molecules of MW under 1.000 Da.
Along with pore size, the degree of 2B oligomerization might
be conditioned by the lipid composition of the membranes.
The formation of this hydrophilic pore by poliovirus 2B is a
hallmark in our knowledge of viroporins. Besides ions, small
molecules can pass through these pores; a behavior that
is very similar to that noted in animal virus-infected cells
[35].
6. Alphavirus 6K
Alphavirus 6K is synthesized as part of a larger precursor
that is proteolytically cleaved [40]. Immediately after synthesis
and prior to exit from the endoplasmic reticulum, the 6K
protein could form a complex with E1 and p62 (precursors
of E2 and E3), persisting as such during transport to the cell
surface [41]. Mature glycoproteins become incorporated in the
new virions, whereas 6K is mostly excluded [41,42]. The 6K
protein crosses the membrane once and only its N-terminus is
located in the ER lumen [15]. 6K has several roles : it provides
sites for protease cleavage, it may participate in viral glyco-
protein tra⁄cking and, ¢nally, 6K enhances membrane per-
meability [43^45]. Alphavirus 6Ks are composed of about
60 residues (Table 1), including a long stretch of very hydro-
phobic amino acids that confer the capacity to interact with
membranes [40]. Some amino acids are acylated, increasing
their ability to persist on the membranes [40]. Recently, a
domain able to become partitioned among membranes was
identi¢ed in Sindbis virus 6K [17]. This domain is required
to enhance membrane permeability. The individual expression
of 6K promotes membrane permeabilization [17,45]. These
studies have been complemented by the analysis of 6K-de¢-
cient togavirus variants. The 6K protein is not essential for
virus particle formation, nor for early viral infection steps
such as the binding, uptake and uncoating of the infecting
virus along with the formation of early non-structural virus
protein [46,47]. Total deletion of the 6K gene still permits
virus replication, although virus yields are diminished
[48,49]. 6K-de⁄cient viruses retain their capacity for glyco-
protein processing, virus budding being the most a¡ected
step of virus replication [49,17]. It has been suggested that
6K might exert its actions on glycoprotein packing and on
its interaction with membrane lipid [50]. Interestingly, Sindbis
viruses that lack 6K are compensated, at least in part, by the
synthesis of HIV-1 Vpu [51]. The recent discovery of a cation-
selective ion channel activity of 6K proteins from BFV and
RRV, when inserted into planar lipid bilayers [15], has opened
new routes for further exploring the mechanisms of action of
alphavirus 6K protein.
7. HIV-1 Vpu
HIV-1 Vpu is an oligomeric, type I transmembrane phos-
phoprotein [52^54]. Vpu is translated from a bicistronic
mRNA that also encodes the envelope glycoprotein. The
vpu gene is unique to HIV-1, it is not encoded by HIV-2,
nor by simian lentivirus with the exception of SIVcpz. How-
ever, the envelope glycoprotein of lentivirus may display Vpu-
like activity in the absence of Vpu protein [23]. The HIV-1
Vpu protein contains 81 amino acid residues distributed along
an N-terminal hydrophobic region of 27 amino acid residues
and a C-terminal hydrophilic region, connected by a short
stretch of basic amino acid residues (Fig. 1). In the HIV-1
life cycle, Vpu has at least two roles that correspond to two
domains.
The N-terminal transmembrane segment is critical for Vpu
enhancement of virus particle release from infected cells [55].
The C-terminal cytoplasmic domain is required for CD4 deg-
radation in host cells [56]. Most Vpu protein localizes at the
ER and the Golgi apparatus; a small amount of protein,
which is nevertheless excluded from the virus particles, local-
izes at the cytoplasmic membrane [57,58]. According to this
cellular location, Vpu induces modi¢cations in compartments
in the secretory pathway and the cell membrane. Thus, Vpu
impairs normal tra⁄cking of membrane proteins other than
CD4, such as MHC-I and alphavirus glycoproteins [51,59]. In
addition, Vpu disrupts cell membrane integrity, inducing per-
meability to small molecules upon expression in Escherichia
coli and in mammalian cells [60]. According to secondary
structure predictions, Vpu and lysin from red abalone (Ha-
liotis rufescens) have been reported to be similar [61].
Several lines of evidence re£ect the ion channel activity of
Vpu. Puri¢ed Vpu forms ion channels with a slight preference
for cations in planar lipid bilayers [62]. When expressed in
Xenopus oocytes, Vpu increases cation-selective membrane
conductance [63]. Further, it has recently been shown that
amiloride derivatives block Vpu ion channel activity [64].
However, the Vpu protein and its mRNA are both unstable
in oocytes. There is some dispute over whether Vpu acts as an
ion channel at the cell surface or only as an intracellular ion
channel [65,66].
The Vpu protein contains three helical units, one of which
is an amphipathic transmembrane helix. Synthetic Vpu trans-
membrane helices have been shown to self-assemble in a lipid
bilayer to form channels [63]. Molecular-dynamic simulations
of ion channels formed by bundles of Vpu transmembrane
helices suggest the most likely channel assembly is a pentamer,
but higher or lower order oligomers may also be formed [16].
Further studies based on FTIR spectroscopy, combined with
a global molecular-dynamics search protocol, indicate that
tryptophans may occlude the pore of the pentameric bundle
of helices by forming a stable assembly, whereas the gating
mechanism might consist of conformational changes that take
place in the transmembrane peptide [67]. When extended
transmembrane segments of Vpu were used, arginines (Arg
31) pointed into the pore, forming a positive charged ring
that could act as a putative selectivity ¢lter [68].
Despite Vpu’s multifunctional role in the virus life cycle,
HIV-1 carrying a truncated vpu gene is still able to replicate.
The steps a¡ected in vpu-de¢cient variants are the correct
assembly and exit of virus particles [69]. A large proportion
of mutant particles remains attached to the cell surface, the
size and shape of these progeny virions also being altered. In
good agreement with these ¢ndings, vpu expression is able to
correct defects in Sindbis viruses lacking the 6K gene [51].
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8. In£uenza virus M2
The M2 protein is encoded by a small genomic in£uenza
virus RNA fragment [65]. This RNA fragment also codes for
another protein, known as M1. M2 or M1 synthesis occurs on
di¡erent mRNAs, generated by di¡erential splicing. M2 is a
type III integral membrane phosphoprotein made up of 96
amino acids, which can be divided into three regions: an
extracellular 23-residue fragment, a 19-amino acid transmem-
brane domain and a ¢nal 54 residues comprising the cytoplas-
mic tail [65]. The M2 protein forms homo-oligomers whose
active state is a tetramer. A breakthrough in elucidating M2
functioning emerged from studies on its individual expression
in Xenopus laevis oocytes [70]. M2 synthesis in this system
leads to increased permeability towards ions, with the conse-
quent decrease in membrane potential. The current M2 activ-
ity model indicates this protein may act at two di¡erent stages
during in£uenza virus infection (see reviews [65,71]). M2 al-
lows the entry of protons into virions, promoting virus un-
coating in endosomes [72]. In addition, the ion channel activ-
ity of M2 might lead to a pH balance in in£uenza virus-
infected cells, between that of the acid lumen of the TGN
and the pH of the cytoplasm [72^74]. Detailed analyses of
the structure and function of M2 as an ion channel are re-
viewed in this issue.
M2 also has e¡ects on glycoprotein processing and tra⁄ck-
ing. The M2 protein impairs the correct glycosilation of the
viral glycoprotein and slows HA delivery to the plasma mem-
brane [74,75]. In addition, M2 reduces the apical secretion of
cellular proteins in MDCK cells [76,77].
The antiviral compound amantadine, which blocks the en-
try of all strains of in£uenza virus [78], inhibits M2 [73] and
also hinders the proper budding of virus particles [79].
In direct contrast to the above model of M2 functioning is
the ¢nding that this protein increases membrane permeability
to small molecules, as occurs with other viroporins [80].
Moreover, in£uenza virus entry does not occur at low pH
when the pH gradient is destroyed [12,81]. An M2-de¢cient
variant is able to undergo multiple cycles of replication in
cultured cells, further suggesting that M2 is not essential for
virus entry [82]. In this M2-de¢cient variant, virus production
is decreased with respect to wild-type in£uenza virus [82,83],
consistent with observations in other animal viruses lacking
the viroporin gene [49,69]. The possibility that M2 activity is
di¡erentially required for infectivity according to virus strain
has been argued [83].
9. Other viroporins
As well as the viroporins described above, there are other
examples that have received less attention. The structural fea-
tures of a number of animal virus proteins ¢t in well with the
typical viroporin structure. In some cases their membrane
permeabilization capacity has also been proven. This is true
of the SH protein of respiratory syncytial virus and the p10
protein of avian reovirus [84,85]. Another recent example is
the small hydrophobic protein, p7, that resembles alphavirus
6K, encoded by species of the Flaviviridae family. Human
hepatitis C virus (HCV) p7 has been found to be associated
with secretory pathway compartments, a small fraction also
being located at the plasma membrane [86]. HCV p7 forms
hexamers and functions as a calcium channel in black lipid
membranes [87]. Further, the p7 protein of bovine viral diar-
rhea virus (BVDV) facilitates virus release from the plasma
membrane [88]. A nice example of a potassium channel pro-
tein encoded by algae virus corresponds to Kcv protein from
Paramecium bursaria chlorella virus (PBCV-1) [89,90]. The
Kcv protein contains two membrane-spanning domains linked
by a strech of 44 amino acids. Kcv fused to GFP has a pref-
erential localization at the endoplasmic reticulum and much
less at the plasma membrane [91].
Other proteins proposed as viroporins because of their
structural features need further investigating to establish their
membrane permeabilization capacity. One promising candi-
date is the 10.6 kDa polypeptide encoded by the alpha 1
ORF gene in bovine ephemeral fever rhabdovirus (BEFV).
This protein has the hydrophobic and highly basic regions
characteristic of a viroporin, but its functional role remains
to be explored [92]. Recently, a new vaccinia virus gene,
A14.5L ORF, has been predicted to encode a hydrophobic
Fig. 2. Schematic representation of the pore formed by viroporins.
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protein comprised of 53 amino acids. Although the A14.5L
product is not essential for virus replication in tissue-cultured
cells, deletion of this gene reduces the virulence of vaccinia
virus in mice [93].
Several phage proteins also show the typical viroporin
structure [94]. These proteins are able to modify membranes
and can open large pores in bacterial cells. Because of this
capacity, they have been denoted holins. To our knowledge,
no viroporins have been described in plant viruses. The anal-
ysis of plant virus genomes could, nonetheless, uncover their
existence. Indeed, this could be the case for the small hydro-
phobic protein (p6) of Closteroviruses, which is known to be
involved in virus movement from cell to cell [95].
10. Future prospects
Despite signi¢cant developments in the ¢eld of viroporins
since our last review on this topic, we foresee that this decade
will bring further insight into this fascinating group of viral
proteins. Several questions related to the functions of viropor-
ins await clari¢cation and future research lines will no doubt
attempt to address questions such as the following.
10.1. Subcellular localization of viroporins
Immunolocalization studies performed on virus-infected
cells indicate that most of the viroporin is located intracellu-
larly, while little or none is detected at the plasma membrane.
This might suggest that viroporin acts by releasing a signal
from an intracellular compartment to the plasma membrane,
where viroporin activity is detected. Alternatively, perhaps
only the small amounts of viroporin observed at the plasma
membrane can account for the enhanced membrane perme-
ability. By retaining some viroporins at intracellular compart-
ments, it has been possible to block their membrane perme-
ability enhancing capacity. This suggests the protein needs to
reach the plasma membrane to act. Finally, it should be kept
in mind that the destiny of a viroporin could be determined or
modulated by the synthesis of other viral components [37].
10.2. Interaction of viroporins with other molecules
Another question of interest would be to determine if viro-
porins interact with other viral or cellular proteins. If this
were the case, viroporin tra⁄cking through the vesicle system
could be regulated, as could the formation of the actual pore.
For instance, if a viroporin molecule interacts with a given
viral glycoprotein, dissociation of this interaction could pro-
mote viroporin oligomerization and pore formation [41,96].
10.3. Ion channels or hydrophilic pores
An essential point that needs to be established is whether
viroporins form pores allowing the passage of di¡erent ions
and small molecules or if their architecture itself corresponds
to speci¢c ion channels with a controlled gating mechanism
[71]. In general, ion channels are selective for a given ion and
do not permit the passage of other ions or molecules. More-
over, the gating of these channels is regulated. Phenomena
observed in virus-infected cells or in systems that express
some of these viroporins would appear to indicate the pres-
ence of pores at the plasma membrane (Fig. 2).
10.4. Which is their exact mode of action?
The key question is to understand, in molecular terms, how
a protein that forms pores can enhance virus budding from
cells. A possibility is that the dissipation of ionic gradients in
regions of virus assembly promotes virion exit from cells [97].
10.5. Are there di¡erent viroporin subfamilies?
The discovery of new viroporins and subsequent analysis of
their activity will provide information on the molecular uni-
formity of this group of proteins. Present knowledge suggests
there are di¡erent viroporin subfamilies, since their structure
and function di¡er when analyzed in detail. This question
would need to be addressed by comparative studies on several
viroporins.
10.6. Viroporins and antiviral chemotherapy
The fact that some compounds such as amiloride deriva-
tives or amantadine are able to block Vpu, M2 and p7 sug-
gests the possibility of ¢nding additional selective agents to-
wards viroporin function. Inhibiting viroporin activity would
lead to diminished virus production. This alone might be suf-
¢cient for the immune system to eradicate the virus infection.
Nonetheless, regardless of their therapeutic potential or lack
of anti-viral activity, new anti-viroporin compounds will be
extremely useful for evaluating the mode of action of these
proteins in cell culture systems.
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